Highlights MedinCell LIQUIDNET SYSTEMS

Equities

FR0004065605

End-of-day quote LIQUIDNET SYSTEMS Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

15/05	Medincell: share price falls after disappointing clinical study	CF
15/05	Transcript : MedinCell S.A. - Special Call

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medincell: share price falls after disappointing clinical study	15/05	CF
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial	14/05	CI
Medincell: share price rises on resumption of trading	09/05	CF
CAC40: remains in green in a neglected market	08/05	CF
Medincell: positive results in schizophrenia	08/05	CF
Medincell Listing Temporarily Suspended on Euronext Paris	08/05	MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study	08/05	RE
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	08/05	CI
Medincell: share price rises following agreement with AbbVie	17/04	CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics	16/04	DJ
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies	16/04	CI
Medincell: Unitaid grant to combat malaria	09/04	CF
Medincell Receives $6 Million Extension Grant from Unitaid for Malaria Drug Trial	09/04	MT
Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy? for the Treatment of Schizophrenia	15/03	CI
Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable	09/01	CI
MedinCell: first-half net loss reduced	20/12	CF
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2023	19/12	CI
Medincell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (Mdc-Cwm), A First-In-Class Therapy for Localized Pain Relief After Total Knee Replacement	30/23/30	CI
MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2023	26/23/26	CI
Global markets live: HSBC, Logitech, Uber, IBM, BP...	02/23/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MedinCell LIQUIDNET SYSTEMS

Equities

FR0004065605

Highlights

Filters